MiNK Therapeutics Inc (NASDAQ: INKT) is a clinical-stage biopharmaceutical company developing cell therapy product candidates. The company generates no product revenue and funds operations through capital raises, as it has no approved products as of the 10-K filed March 31, 2026. MiNK carried R&D expense of $5.8 million for the year ended December 31, 2025, down 9% from $6.3 million in 2024, while G&A expense rose 56% to $6.7 million in 2025 from $4.3 million in 2024, driven by higher professional fees and share-based compensation from an option award modification approved by shareholders in June 2025. The company operates under a stockholders' deficit and has disclosed no committed source of additional capital, relying on future fundraising to continue clinical and pre-clinical activities. Jennifer S. Buell, Ph.D. serves as President and Chief Executive Officer, with Garo H. Armen, Ph.D. as Chairman of the Board. The company was formerly associated with AgenTus Therapeutics, which maintained its own equity incentive plan beginning in 2018.

Revenue model

No product revenue as of the fiscal year ended December 31, 2025. Operations are funded through external capital raises. The company has disclosed no licensing revenue or collaboration payments in the filing excerpts provided.

Products and services

Clinical-stage cell therapy product candidates. No approved products as of the 10-K filed March 31, 2026. Pre-clinical and clinical activities are ongoing, with costs captured in R&D expense of $5.8 million for the year ended December 31, 2025.

Customers and end markets

No commercial customers as of the fiscal year ended December 31, 2025. Target end market is oncology or related disease areas addressed by cell therapy, though specific indications are not detailed in the provided filing excerpts.

Value-chain role

Drug developer at the clinical and pre-clinical stage. The company contemplates future commercialization through either an independent sales organization or third-party distribution arrangements, but neither is in place as of the filing date.

Geographic exposure

Operations subject to U.S. regulations and international compliance requirements including the FCPA and U.K. Bribery Act 2010, and GDPR for any EEA clinical trial activities. Primary jurisdiction of incorporation and operations is the United States.

Source: SEC 10-K, filed 2026-03-31

Industry: Biological Products, (No Diagnostic Substances) Peers: Harvard Apparatus Regenerative Technology Inc Apexigen, Inc. iBio Inc LUMOS PHARMA, INC. Dianthus Therapeutics Inc Onkure Therapeutics Inc Spero Therapeutics Inc Taysha Gene Therapies Inc